$1.7 Million Settlement – Medical Malpractice

Seeger Weiss Obtains $1.7 Million Recovery for Physician’s Failure to Diagnose Renal Disease in Timely Manner In a medical malpractice case pending in Supreme Court, Bronx County, Seeger Weiss came to a $1.7 million settlement agreement earlier this month on behalf of a client who has been diagnosed with end stage renal disease. The case, […]

August 9, 2010

Medical Malpractice

Seeger Weiss Obtains $1.7 Million Recovery for Physician’s Failure to Diagnose Renal Disease in Timely Manner

In a medical malpractice case pending in Supreme Court, Bronx County, Seeger Weiss came to a $1.7 million settlement agreement earlier this month on behalf of a client who has been diagnosed with end stage renal disease.

The case, brought against our client’s primary care physician, alleged that the physician’s failed to recognize signs and symptoms of kidney dysfunction over a period of nearly two years. In addition, this failure to diagnose and treat the client’s condition in its early stages was a significant factor in our client’s current diagnosis of advanced renal disease.

“This case underscores the importance of closely monitoring even routine blood test results,” said Seeger Weiss partner Marc S. Albert. “Simply put, this client’s kidney disease should have been diagnosed much earlier than it ultimately was. Unfortunately, blood tests over nearly a two year period, which showed elevated and continuously rising Creatinine and BUN levels—clear indications of renal disease—were not being carefully reviewed by his physician.”

During the course of the case, our client appeared on a CBS News special highlighting a problem that has become somewhat endemic in the medical field: physicians’ cavalier approach to reviewing patient’s test results. CBS, in a recent news story, reported on a number of patients—including our client—who had serious medical conditions slip through the cracks when test results were not carefully evaluated by their physician.

“We are extremely satisfied with what we feel is a just result for our client in this case,” said Mr. Albert.

Notwithstanding claims relating to this product, the drug/medical device remains approved by the U.S. FDA.

Related News

October 3, 2023
Seeger Weiss Announces $425 Million Settlement with AstraZeneca in Proton-Pump Inhibitor Litigation

Seeger Weiss is pleased to announce a landmark $425 million settlement with AstraZeneca Pharmaceuticals in the Proton-Pump Inhibitor Products Liability Litigation. This significant achievement comes on behalf of thousands of consumers who suffered kidney injuries while using proton-pump inhibitor (“PPI”) medications. Founding partner Chris Seeger serves as co-lead counsel with Stephanie O’Connor of Douglas & […]

Read More
October 2, 2023
Seeger Weiss Founder Chris Seeger Awarded Law360 MVP for Product Liability

Seeger Weiss is pleased to announce that founding partner Chris Seeger was honored with a Law360 2023 MVP award for his product liability practice. This prestigious accolade serves as a testament to Chris’ unyielding commitment to holding corporations accountable and pursuing justice for consumers harmed by defective products. Over the course of the past year, […]

Read More
September 22, 2023
Seeger Weiss Represents City of Chicago in New PCB Lawsuit Against Monsanto

Earlier this week, the City of Chicago filed a lawsuit against Monsanto and other chemical companies seeking damages for widespread contamination of its waterways caused by Polychlorinated biphenyls (PCBs), highly toxic and dangerous chemical compounds known to accumulate in the human body and cause serious health effects. Plaintiffs allege that Monsanto intentionally misled the public […]

Read More